Aclaris Therapeutics, Inc.[ACRS] stock saw a move by -12.27% on Thursday, touching 1.71 million. Based on the recent volume, Aclaris Therapeutics, Inc. stock traders appear to be active. The most recent trading volume of ACRS shares recorded 43.40M shares, which represents the daily volume of traded shares. Analysts estimates state that Aclaris Therapeutics, Inc. [ACRS] stock could reach median target price of $5.00.

Aclaris Therapeutics, Inc. [ACRS] stock additionally went up by +29.44% in the period of the 7 days, recording a gain in performance by 75.25% in the last 30 days. The yearly more of ACRS stock is set at -89.17% by far, with shares price recording returns by -68.10% in the latest quarter. Over the past six months, ACRS shares showcased -74.65% decrease. ACRS saw -91.05% change opposing the low price in the last 12 months, also recording 93.24% compared to high within the same period of time.

Aclaris Therapeutics, Inc. [NASDAQ:ACRS]: Analyst Rating and Earnings

Its stock price has been found in the range of 0.74 to 15.98. This is compared to its latest closing price of $1.63.

Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Tue 5 Nov (In 47 Days).

Fundamental Analysis of Aclaris Therapeutics, Inc. [ACRS]

Now let’s turn to look at profitability: with a current Operating Margin for Aclaris Therapeutics, Inc. [ACRS] sitting at -1329.32 and its Gross Margin at +32.12.

This company’s Return on Total Capital is -56.97, and its Return on Invested Capital has reached -55.10%. Its Return on Equity is -60.28, and its Return on Assets is -50.94. These metrics suggest that this Aclaris Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Aclaris Therapeutics, Inc. [ACRS] has generated a Total Debt to Total Equity ratio of 14.18. Similarly, its Total Debt to Total Capital is 12.42, while its Total Debt to Total Assets stands at 11.07.

What about valuation? This company’s Enterprise Value to EBITDA is 0.72. The Enterprise Value to Sales for this firm is now -5.85, and its Total Debt to Enterprise Value stands at 0.29. Aclaris Therapeutics, Inc. [ACRS] has a Price to Book Ratio of 1.42.

Shifting the focus to workforce efficiency, Aclaris Therapeutics, Inc. [ACRS] earns $59,710 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.78 and its Total Asset Turnover is 0.04. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 6.54 and its Current Ratio is 6.56. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Aclaris Therapeutics, Inc. [ACRS] has 43.40M shares outstanding, amounting to a total market cap of $70.74M. Its stock price has been found in the range of 0.74 to 15.98. At its current price, it has moved down by -91.05% from its 52-week high, and it has moved up 93.24% from its 52-week low.

This stock’s Beta value is currently 0.83, which indicates that it is 15.35% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 56.64. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Aclaris Therapeutics, Inc. [ACRS] a Reliable Buy?

Shares of Aclaris Therapeutics, Inc. [ACRS], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.